Every material Form 8-K Core Laboratories Inc. /DE/ has filed with the SEC since July 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Core Laboratories reported third quarter 2026 revenue of $132.1 million, up 6% from the prior quarter but down 2% from a year earlier, with GAAP diluted EPS of $0.12 versus $0.31 in the third quarter of 2025. The company expects fourth quarter revenue of $128.5 million to $134.5 million, roughly flat sequentially, and the Board approved a $0.01 per share quarterly dividend. Profit is well below last year's level, and the outlook points to little change in near-term revenue.
Q3 2026 revenue of $132.1 million, up 6% from Q2 2026 and down 2% from $134.5 million in Q3 2025
GAAP diluted EPS of $0.12 versus $0.31 a year earlier; EPS excluding items of $0.16, down 27% year over year
Q4 2026 revenue guidance of $128.5 million to $134.5 million, relatively flat sequentially; Q4 EPS expected at $0.12 to $0.20
Quarterly dividend of $0.01 per share, record date November 9, 2026, payable November 30, 2026
Core Laboratories director Kwaku Temeng confirmed in an August 25, 2026 letter that he will resign from the Board effective October 1, 2026. He chairs the Nominating Committee and sits on the Compensation Committee, and his letter cites a disagreement with the Board over strategic direction and certain governance practices.
Kwaku Temeng first notified the Board verbally on August 19, 2026, and confirmed his resignation by letter on August 25, 2026.
Resignation is effective October 1, 2026; he serves as Chairman of the Nominating Committee and as a member of the Compensation Committee.
The Board says the main disagreement involves how the Company handles succession planning, a process a majority of directors supports; the Board also says he has concerns about research priorities.
Temeng has served on the Board for more than five years; his resignation letter is filed as Exhibit 17.1.
Core Laboratories reported second-quarter 2026 revenue of $124.6 million, down 4% from a year earlier but up 2% from the first quarter, and GAAP diluted EPS of $0.13 versus $0.22 a year earlier. The company expects third-quarter revenue of $128.5 million to $135.5 million and EPS of $0.12 to $0.20, and declared a $0.01 per share quarterly dividend.
Q2 2026 revenue $124.6 million, down 4% year-over-year and up 2% sequentially; GAAP operating income $9.2 million
GAAP diluted EPS $0.13 versus $0.22 in Q2 2025; EPS excluding specific items $0.11
Q3 2026 guidance: revenue $128.5 million to $135.5 million; EPS $0.12 to $0.20
Quarterly dividend of $0.01 per share, record date August 10, 2026, payable August 31, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Core Laboratories Inc. /DE/ filing is on SEC EDGAR ↗. 8-K briefs of other companies →